Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

Phase 3(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00337285Phase 3Completed

An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Role: lead

NCT00556296Phase 3Completed

Phase 3 Randomized Double-Blind Placebo-Controlled Study of NRP104 in Children Aged 6-12 With ADHD

Role: lead

NCT00557011Phase 2Completed

NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD

Role: lead

NCT00334880Phase 3Completed

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

Role: lead

NCT00248092Phase 1Completed

Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse

Role: lead

NCT00247572Phase 2Completed

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

Role: lead

All 6 trials loaded